FDA accepts supplemental application for Lucentis to treat Diabetic Retinopathy- Genetech/Roche

Genentech/Roche,has announced that the FDA has accepted to file the company's supplemental Biologics License Application (sBLA) and granted Priority Review of Lucentis (ranibizumab injection) for the treatment of Diabetic Retinopathy, an eye disease that impacts nearly 7.7 million Americans. The FDA confirmed action date is February 6, 2015.

If approved by the FDA, Lucentis could be the first eye medicine available for diabetic retinopathy patients.